Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era

International Journal of Radiation Oncology Biology Physics

Volumn 52, Issue 3, 2002, Pages 704-711

  Kupelian, Patrick A ^a   Buchsbaum, Jeffrey C ^a   Patel, Chandrika ^a   Elshaikh, Mohamed ^a   Reddy, Chandana A ^a   Zippe, Craig ^a   Klein, Eric A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Biochemical relapse free survival; Localized prostate cancer; Overall survival; Radiation dose; Radiotherapy

Indexed keywords

BIOPSY; DOSIMETRY; MULTIVARIABLE SYSTEMS; RADIOTHERAPY;

BIOCHEMICAL FAILURE;

ONCOLOGY;

ANDROGEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONBIOLOGICAL MODEL; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION DOSE; SURVIVAL RATE; TIME OF DEATH; TREATMENT OUTCOME; TUMOR BIOPSY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; SALVAGE THERAPY; SURVIVAL RATE; TIME FACTORS; TREATMENT FAILURE;

EID: 0036499051     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)02778-X     Document Type: Article

References (20)

1. Higher than standard radiation doses (72 Gy or greater) with or without androgen deprivation in the treatment of localized prostate cancer
2. Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis
3. Serum PSA as a tumor marker for patients undergoing definitive radiation therapy
4. Significance of normal serum prostate specific antigen in the follow-up period after definitive radiation therapy for prostate cancer
5. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-Year results
6. Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate
7. Conventional vs. conformal radiotherapy for prostate cancer: Preliminary results of dosimetry and acute toxicity
8. Failure pattern implications following external beam irradiation of prostate cancer: Long-term follow-up and indications of cure
9. Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy
10. Prostate-specific antigen cancer volume: A significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy
11. Prognostic factors in prostate cancer: Prostate specific antigen: An important marker for prostate cancer treated by external beam radiotherapy
12. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy
13. Prostate-specific antigen and external beam radiation therapy in prostate cancer
14. Dose selection for prostate cancer patients based on dose comparison and dose response studies
15. Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions
16. Preliminary results of a randomized dose-escalation study comparing 70 Gy to 78 Gy for the treatment of prostate cancer
17. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer
18. Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy
19. Improvement in overall survival for patients with localized prostate cancer with higher than standard radiation doses: Preliminary results
20. Declining rates of extracapsular extension after radical prostatectomy: Evidence for continued stage migration